245 related articles for article (PubMed ID: 12534550)
1. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors.
Birnbaum J; Ramadour M; Magnan A; Vervloet D
Clin Exp Allergy; 2003 Jan; 33(1):58-64. PubMed ID: 12534550
[TBL] [Abstract][Full Text] [Related]
2. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
3. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
Müller U; Helbling A; Berchtold E
J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.
van Halteren HK; van der Linden PW; Burgers JA; Bartelink AK
J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 1):767-70. PubMed ID: 9438484
[TBL] [Abstract][Full Text] [Related]
7. A simple 3-day "rush" venom immunotherapy protocol: documentation of safety.
Kalogeromitros D; Makris M; Koti I; Chliva C; Mellios A; Avgerinou G; Theoharides TC
Allergol Immunopathol (Madr); 2010; 38(2):69-73. PubMed ID: 19853357
[TBL] [Abstract][Full Text] [Related]
8. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rush immunotherapy in patients with Hymenoptera allergy in Japan.
Hirata H; Asakura T; Arima M; Cheng G; Honda K; Fukushima F; Yamaguchi B; Yoshida N; Fukuda T
Asian Pac J Allergy Immunol; 2003 Jun; 21(2):89-94. PubMed ID: 14629126
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of Hymenoptera venom allergy.
Biló BM; Rueff F; Mosbech H; Bonifazi F; Oude-Elberink JN;
Allergy; 2005 Nov; 60(11):1339-49. PubMed ID: 16197464
[TBL] [Abstract][Full Text] [Related]
11. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
12. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy.
Gawlik R; Glück J; Jawor B; Rogala B
Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651
[TBL] [Abstract][Full Text] [Related]
13. Sublingual desensitization in patients with wasp venom allergy: preliminary results.
Patriarca G; Nucera E; Roncallo C; Aruanno A; Lombardo C; Decinti M; Pascolini L; Milani M; Buonomo A; Schiavino D
Int J Immunopathol Pharmacol; 2008; 21(3):669-77. PubMed ID: 18831935
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and clinical relevance of specific immunoglobulin E to pollen caused by sting- induced specific immunoglobulin E to cross-reacting carbohydrate determinants in Hymenoptera venoms.
Kochuyt AM; Van Hoeyveld EM; Stevens EA
Clin Exp Allergy; 2005 Apr; 35(4):441-7. PubMed ID: 15836751
[TBL] [Abstract][Full Text] [Related]
15. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols.
Birnbaum J; Charpin D; Vervloet D
Clin Exp Allergy; 1993 Mar; 23(3):226-30. PubMed ID: 8472191
[TBL] [Abstract][Full Text] [Related]
16. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients.
Sturm G; Kränke B; Rudolph C; Aberer W
J Allergy Clin Immunol; 2002 Dec; 110(6):928-33. PubMed ID: 12464961
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing venom immunotherapy: extended observations.
Golden DB; Kwiterovich KA; Kagey-Sobotka A; Lichtenstein LM
J Allergy Clin Immunol; 1998 Mar; 101(3):298-305. PubMed ID: 9525443
[TBL] [Abstract][Full Text] [Related]
18. Natural history of Hymenoptera venom allergy in Eastern Spain.
Fernandez J; Soriano V; Mayorga L; Mayor M
Clin Exp Allergy; 2005 Feb; 35(2):179-85. PubMed ID: 15725189
[TBL] [Abstract][Full Text] [Related]
19. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
Haeberli G; Brönnimann M; Hunziker T; Müller U
Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741
[TBL] [Abstract][Full Text] [Related]
20. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]